| Literature DB >> 23710370 |
Mathew Yamoah Kyei1, Edward James Mensah, Samuel Gepi-Attee, Devine Kwami, Kwabena Ampadu, Emmanuel Asante, George Oko Klufio, Edward Donkoh Yeboah.
Abstract
Background. There is a lack of expertise in the procedure of open radical retropubic prostatectomy in West Africa therefore necessitating the training of urologists in the subregion in this procedure. Aim. This report looks at the early outcomes of a single surgeon in this procedure after an SIU fellowship. Methodology. A prospective study of the initial twenty consecutive patients with clinically localized prostate cancer that underwent open radical retropubic prostatectomy at the Korle Bu Teaching hospital, Accra. Results. The mean followup was 19.5 months (range 7 months-36 months). The mean age was 62.7 yrs. For the clinical stage, 60% were T1c and 40% T2a with a mean Gleason score of 6.5. The mean estimated blood loss was 1140.0 mLs with a transfusion rate of 70%. For the pathologic stage, pT2 cancers formed 60%, pT3 25%, and pT4 5% with a mean Gleason score of 6.8. No lymph node involvement was noted. The perioperative complications rate was 15%, a postoperative potency recovery rate of 78.6% with all the patients being continent of urine. The tPSA of 95% of the patients had remained less than 0.4 ng/mL. Conclusion. The SIU scholarship offers an avenue for training in radical prostatectomy for sub-Saharan Africa.Entities:
Year: 2013 PMID: 23710370 PMCID: PMC3655646 DOI: 10.1155/2013/832496
Source DB: PubMed Journal: ISRN Urol ISSN: 2090-5807
Table showing the patients clinical presentation.
| Presentation | No. (%) |
|---|---|
| Lower urinary obstructive symptoms | 8 (40) |
| Acute retention of urine | 6 (30) |
| Routine screening by PSA | 5 (25) |
| Pelvic pain | 1 (5) |
|
| |
| Total | 20 (100) |
Estimated blood loss during radical prostatectomy.
| Estimated blood loss (mls) | No. (%) |
|---|---|
| <500 | 0 (0.0) |
| 500–999 | 8 (40.0) |
| 1000–1499 | 7 (35.0) |
| 1500–1999 | 3 (15.0) |
| 2000–2499 | 0 (0.0) |
| ≥2500 | 2 (10.0) |
Table showing clinical stage at diagnosis (trus biopsy) versus pathological stage of the prostate cancer.
| Serial number | Age (yrs) | tPSA (ng/mL) | Clinical stage | Pathological stage |
|---|---|---|---|---|
| 1 | 63 | 7.60 | T1c 3 + 3 | BPH |
| 2 | 72 | 7.90 | T2a 3 + 4 | T3b 4 + 3 (no lymph nodes) |
| 3 | 55 | 62.20 | T1c 3 + 3 | T3b 4 + 3 N0 |
| 4 | 69 | 11.10 | T1c 3 + 4 | T3b 4 + 5 N0 |
| 5 | 61 | 8.30 | T2a 3 + 2 | BPH (no lymph nodes) |
| 6 | 62 | 2.45 | T2a 3 + 3 | T2b 3 + 3 N0 |
| 7 | 63 | 28.00 | T1c 4 + 3 | T4 3 + 3 N0 |
| 8 | 63 | 7.60 | T1c 3 + 3 | T2a 3 + 3 N0 |
| 9 | 55 | 13.60 | T1c 4 + 3 | T2a 4 + 5 (no lymph nodes) |
| 10 | 66 | 8.80 | T2a 3 + 3 | T3b 4 + 3 N0 |
| 11 | 58 | 39.39 | T2a 3 + 3 | T2b 4 + 3 N0 |
| 12 | 60 | 7.01 | T1c 3 + 3 | T2a 3 + 3 N0 |
| 13 | 60 | 12.00 | T2a 3 + 3 | T2b 3 + 3 N0 |
| 14 | 72 | 13.00 | T2a 4 + 3 | T2b 4 + 3 N0 |
| 15 | 51 | 14.03 | T1c 4 + 3 | T2a 4 + 3 N0 |
| 16 | 59 | 9.00 | T1c 4 + 3 | T2c 3 + 4 (no lymph nodes) |
| 17 | 67 | 13.99 | T1c 4 + 5 | T2c 3 + 3 (no lymph nodes) |
| 18 | 65 | 19.00 | T1c 3 + 3 | T2b 3 + 3 N0 |
| 19 | 64 | 21.17 | T2a 4 + 3 | T3a 3 + 4 N0 |
| 20 | 69 | 16.30 | T1c 3 + 4 | T2a 3 + 4 N0 |